Security Stocks; Visualant (OTCBB:VSUL) Subsidiary TransTech Systems Announces Access Card Programmer Incorporated in ID Card Printers

SEATTLE - April 12, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has successfully incorporated an industry standard access card programmer into an identification card printer for production of personalized access control credentials.

Traditionally, access cards are pre-programmed by providers and shipped to the users for future use. At the time of card issuance, there is a two step process whereby the card is read by an access reader to get the pre-programmed number associated with the card and then the card is printed with the card holder's information. With TransTech's integration of Farpointe Data's Cards on the Go™ COG1000 directly into the printer, the process can be accomplished in one step. Further, the requirements for ordering pre-programmed stock and the related worries about the security of this stock before issuance are eliminated.
Cards on the Go™ COG-1000 is an access control credential programmer designed to give security access control professionals and system integrators the ability to program both proximity and contactless smartcard credentials. The Cards on the Go™ COG-1000 desktop solution includes a USB-based desktop programmer, a USB cable, programming software and 100 preloaded programming tokens. The Cards on the Go™ card printer based solution configuration will vary by printer manufacturer. OEM solutions for larger systems integrators may be available.
Adding Cards on the Go™ technology to identification card printer solutions provides a unique product offering for TransTech's security reseller channel. TransTech Systems is currently the only provider of this technology. The unit was debuted at the ISC West Security Industry trade show in Las Vegas last week. Full production is planned within sixty days.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
About Farpointe Data
Since 2003 Farpointe Data (www.farpointedata.com), a privately held company located in California�s Silicon Valley, has offered radio frequency identification (RFID) readers, cards and tags for access control. These advanced products span the frequency spectrum, each including a host of unique Farpointe-only features. These products include the 125-kHz Pyramid Series Proximity� line of proximity readers, cards and tags, the Delta™ line of multi-technology (combining 13.56-MHz & 125-kHz operation) contactless smartcard readers, cards and tags, as well as the 433-MHz Ranger™ line of long-range transmitters and receivers.
Farpointe's exacting RFID designs, superior manufacturing, competitive pricing and excellent performance have earned the trust of its partners, access control system manufacturers, and achieved recognition as the industry's leading independent manufacturer of readers, cards and tags.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation

SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier� to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.

"We are grateful to those organizations that collaborated in beta-testing the capabilities of ELLSA to detect exosomes, which are increasingly being recognized as particles that deplete immune cells or provide a mechanism to transport disease-enhancing factors below the surveillance of the immune system,� stated Aethlon CEO, Jim Joyce. "Additionally, the ESI ELLSA provides the potential for a near-term revenue stream that complements the therapeutic programs we are actively advancing at Aethlon Medical"
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Biotech/ Biodefense Sector Trading Alert Stocks Include; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX ), (NasdaqGM: SIGA

Point Roberts, WA- April 8, 2011 - Investorideas.com, a leader in investor sector research
including Biotech and Biodefense Stocks issues a trading alert on the sector for morning trading
April 8th. Stocks Include; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX:
PLX and (NasdaqGM: SIGA ).

The iShares Nasdaq Biotechnology Index (NasdaqGM: IBB ) is trading up at 102.37, up 0.19
(0.19%).

Biotech/ Biodefense Stocks Sector Snapshot
Aethlon Medical (OTCBB: AEMD) trading at$0.12, up 0.01 (4.35%)
Dynasil Corporation (NASDAQ GM: DYSL) trading at$ 4.35, up 0.02 (0.46%)
Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $24.70, down 0.04 (0.16%)
PharmAthene, Inc. (NYSE Amex: PIP) trading at $3.21, down 0.07 (2.12%)
Protalix BioTherapeutics, Inc. (AMEX: PLX ) trading at $6.63, up 0.20 (3.11%)
Siga Technologies (NasdaqGM: SIGA ) trading at $13.39, up 0.08 (0.60%) 10:32AM EDT

Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Research Biotech Stocks at Investorideas.com
http://www.investorideas.com/BIS/Stock_List.asp

Daily Finance’s recent article, “Inside Wall Street: Looking to the Bio-Defense Sector as
Nuclear Fears Mount”, notes - The sector attracted a lot of interest after 9/11 and a number of
companies emerged to develop protective biodefense drugs and products. But with the waning of
dark headlines about terrorist threats, investors have tended to put them on their low-priority list.
That may be about to change

Full article: http://www.dailyfinance.com/story/stock-picks/inside-wall-street-looking-to-bio-defense-sector-as-
nuclear-fea/19880106/

Biotech/ Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD), Protalix
BioTherapeutics, Inc. (AMEX: PLX )

Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer.
Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in
disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious
viruses and immunosuppressive proteins from the entire circulatory system. We recently
discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune
system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly
inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in
cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet
clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or
interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:

James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

Recent News: Shareholder Letter
http://www.investorideas.com/CO/AEMD/news/2011/04061.asp

Visit the Aethlon Medical (OTCBB: AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get added to the company’s news alerts:
http://www.investorideas.com/Resources/Newsletter.asp

Protalix BioTherapeutics, Inc. (AMEX: PLX )
Protalix is a biopharmaceutical company focused on the development and commercialization of
recombinant therapeutic proteins expressed through its proprietary plant cell based expression
system, ProCellEx™. Protalix's unique expression system presents a proprietary method for
developing recombinant proteins in a cost-effective, industrial-scale manner in an environment
free of mammalian components and viruses. Protalix's lead compound taliglucerase alfa,
an enzyme replacement therapy for the treatment of Gaucher disease, completed Phase III
development. To date, marketing applications have been submitted for taliglucerase alfa in the
United States, European Union, Brazil and Israel. Protalix's development pipeline also includes:
PRX-105, a pegylated recombinant human acetylcholinesterase in development for several
therapeutic and prophylactic indications, a biodefense program and an organophosphate-based
pesticide treatment program; PRX-102, a modified version of the recombinant human alpha-GAL-
A protein for the treatment of Fabry disease; an orally-delivered glucocerebrosidase enzyme that
is naturally encased in carrot cells, also for the treatment of Gaucher disease; and pr-antiTNF, a
biosimilar version of etanercept (Enbrel™) for the treatment of rheumatoid arthritis.

About www.InvestorIdeas.com

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, including biotech stocks with its portal BiotechIndustryStocks.com.

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make

recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated
by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD )
Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five
thousand per month in 144 stock)Effective March 15, 2011
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Security Stocks; Tobin Smith of NBT Equity Group Interviews Visualant (OTCBB:VSUL) CEO

SEATTLE - April 7, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., announced today that Tobin Smith of NBT Equity Research LLC has released an interview with Visualant Chairman and Chief Executive Officer Ron Erickson. The interview can be accessed through the Visualant website at www.visualant.net or on the NBT Equity Research website at http://nbtequitiesresearch.com/company/visualant-vsul/nbt-tv.

NBT Equity Research LLC is a member of the NBT Equity Group LLC. They were founded by well known research analyst Tobin Smith. Tobin Smith is a contributing market analyst for Fox News Channel and a regular panelist on its highly rated "Bulls & Bears" weekly investment program.
On January 24, 2011, Tobin Smith issued a research report on Visualant which he supplemented on February 11, 2011. Both research reports can be accessed through the Visualant website at www.visualant.net.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Security Stocks; TransTech Systems, a Subsidiary of Visualant (OTCBB:VSUL), to Distribute Farpointe Data's Access Card Programmer

SEATTLE - April 6, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has been chosen to distribute Farpointe Data's new field programmer for access control credentials.

This week Farpointe Data has launched their new CoG-1000 Cards on the Go™ Multi-Technology Field Programmer. Farpointe Data manufactures access control card readers and credentials for many of the leading building access control systems in the market today. TransTech Systems, Farpointe Data's key distributor in the Americas, has been chosen to market the new CoG-1000 field access card programmer.
Scott Lindley, President of Farpointe Data, said, "Cards on the Go™ is a move to address a number of concerns of our customers, including the compressing of lead times and inventories of access credentials, while still providing the security. We are pleased to have TransTech Systems supporting their significant dealer channel with the new Cards on the Go™ solution."
Cards on the Go™ is a stand-alone access control credential programmer designed to give security access control professionals and system integrators the ability to program both proximity and contactless smartcard credentials. It is capable of producing one card at a time, as well as producing larger runs. The Cards on the Go™ solution includes a USB-based desktop programmer, a USB cable, programming software and 100 preloaded programming tokens. Various add-ons and enhancements to the Cards on the Go™ solution are planned for release during 2011. Additional tokens can be ordered through TransTech as well.
"Adding Farpointe Data's technology to our offering brought a very strong and reliable product line to our customer base," said Jeff Kruse, TransTech Systems General Manager. "The Cards on the Go™ solution is fairly unique in the current marketplace and should provide real opportunity for our channel partners."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Releases Shareholder Letter

SAN DIEGO - April 6, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.

To our Shareholders:
On April 1st, we submitted a contract response to the Defense Advanced Research Projects Agency (DARPA) related to the Dialysis Like Therapeutics (DLT) program referenced in my last shareholder letter. In our submission, we proposed to leverage our technology platform to deliver a dialysis-like therapy that would address precursors to sepsis, including bacterial toxins, viral pathogens, and disease enhancing particles transported by exosomes. We believe our proposal meets goals underlying the DLT program as the resulting device would target to reduce the occurrence of sepsis and would provide decision-free and life saving medical care for the wounded warfighter. Additionally, we introduced an innovative strategy to deliver our dialysis-like therapy without the need for anticoagulants, as well as a novel approach to selectively clear whole bacteria from circulation.
If selected for an award, several larger organizations and industry thought leaders have agreed to partner with us to advance our program proposals. It is anticipated that the DLT program awards will be announced in the next 120 days. We are now collaborating with our advisors to determine the next contract or grant opportunity to pursue. Beyond non-dilutive bioterror and pandemic threat funding opportunities, we are also evaluating potential responses to new government programs in Hepatitis-C, HIV, and Cancer.
In addition to navigating government funding opportunities, we are actively advancing research and clinical initiatives in both infectious disease and cancer. On the clinical front, I am pleased to disclose that we our close to submitting our updated IDE to the FDA. The goal of our submission is approval from the FDA to initiate Hemopurifier� human studies in the United States. Details regarding our FDA communications and clinical site locations can be expected through forthcoming news disclosures.
In regards to our HCV treatment study in India, we initiated treatment of our first patient at the Medanta Medicity Institute, which was observed by our President, Rod Kenley. In previous studies, we demonstrated significant viral load reductions in health compromised dialysis patients that were infected with either HCV or HIV. In this study, we are leveraging those results to demonstrate that our Hemopurifier� can accelerate viral load reduction when administered to non-dialysis patients in combination with drug therapy. Based on a prior clinical validation, we are confident in our capabilities and recognize the potential significance of our Hemopurifier� as viral load depletion rates in the earliest stages of therapy are considered predictive of patients who achieve long-term clinical benefit. In the treatment of our first patient, it was recognized early on that that we needed to modify our protocol to administer anticoagulants in dosages specific to our therapy, and not in amounts normally administered to dialysis patients. Regardless, there was no harm to this patient, although the anticoagulant miscalculation did not allow him to successfully complete his entire treatment. While causing a delay of several weeks, our protocol has been formally amended and we are now ramping up patient enrollment. We are also seeking to open up our study to those residing outside of India, based on worldwide inquiries from infected individuals.
In closing, I also wish to disclose that Jeff Richardson has agreed to rejoin our team on a part-time basis. While you may or may not recall Jeff, he was responsible for originating national news coverage our technology through multiple media outlets, including Popular Science, CNN, and Readers Digest. As the former communications director at Amgen, Jeff provides tremendous insight on advancing the awareness of innovative medical therapies through the national media.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, including obtaining government grants, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company's ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Security Stocks; Visualant (OTCBB:VSUL) Spectral Pattern Matching Technology at International Security Conference & Exposition

SEATTLE - April 5, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions and an emerging leader in security and authentication systems technology will be demonstrating its Spectral Pattern Matching (�SPM�) technology at the booth of its wholly-owned subsidiary, TransTech Systems, Inc., at the International Security Conference & Exposition from April 6-8, 2011 at the Sands Expo & Convention Center in Las Vegas, NV.

The International Security Conference & Exposition (ISC West) is one of the fastest growing tradeshows in North America according to the publication Tradeshow Week. With over 23,000 industry professionals and 14,600 security buyers, ISC West is certainly the nation's largest security event of the year. ISC West will be hosting education sessions from April 5-7, 2011 as well as the exposition from April 6-8, 2011. See www.iscwest.com for more information.
Visualant's SPM technology sees color, nature's fingerprint, at the photon level. The SPM technology sees color the counterfeiter cannot see and provides an extra level of security against hacking in the important world of authentication.
See the Visualant SPM technology at TransTech's booth #22129.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)